NCT06711913

Brief Summary

"After spinal anesthesia, some patients may experience shivering, which can be uncomfortable and even lead to complications. Dexmedetomidine is a medication that can help prevent or reduce this shivering. Dexmedetomidine helps to:

  1. 1.Reduces shivering and discomfort.
  2. 2.Improves patient comfort and satisfaction.
  3. 3.Regulates body temperature.
  4. 4.Safe and effective.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Dec 2023

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 21, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2024

Completed
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 21, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 21, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 2, 2024

Completed
Last Updated

December 2, 2024

Status Verified

November 1, 2024

Enrollment Period

6 months

First QC Date

November 21, 2024

Last Update Submit

November 27, 2024

Conditions

Keywords

shivering, dexmedetomidine, neuraxial anesthesia

Outcome Measures

Primary Outcomes (1)

  • Shivering

    Crossley and Mahajan grading of intraoperative shivering Grade 0: no shivering grade 1:no visible muscle activity but piloerection, peripheral vasoconstriction, or both present grade 2: muscular activity in one muscle group grade 3: muscle activity in one than more muscle group

    3 minutes following infusion

Study Arms (2)

Intervention group

ACTIVE COMPARATOR

Received intravenous dexmedetomidine

Drug: Dexmedetomidine

Control group

PLACEBO COMPARATOR

control group receive normal saline

Other: Normal Saline (Placebo)

Interventions

intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes

Intervention group

control group receive normal saline as placebo

Control group

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Elective Cesarean section
  • Age limit 18 to 35 years
  • ASA II

You may not qualify if:

  • Emergency cesarean delivery
  • hypersensitive to dexmedetomidine
  • Pateint with hear, renal, or hepatic diseases requiring follow up
  • Pre-eclemptic pateint
  • Patient with GA
  • Combined spinal epidural anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Liaquat National Hospital and Medical College

Karachi, Sindh, Pakistan

Location

Related Links

MeSH Terms

Interventions

DexmedetomidineSaline Solution

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Ghulam Fatima kharl

    Liaquat national hospital and medical college

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 21, 2024

First Posted

December 2, 2024

Study Start

December 21, 2023

Primary Completion

June 15, 2024

Study Completion

June 21, 2024

Last Updated

December 2, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Reasons of why individual participant data (IPD) may not be shared: 1. \*Patient confidentiality\*: Sharing IPD could compromise patient confidentiality 2. \*Informed consent\*: Participants may not have provided informed consent for their data to be shared, which could raise ethical concerns. 3. \*Data storage and security\*: Sharing IPD requires ensuring the security and integrity of the data, which can be a significant technical challenge.

Locations